This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech

Why Prothena (PRTA) Stock Is Up Today

Why Prothena (PRTA) Stock Is Up Today

  • Tickers in this article:
  • PRTA

Prothena (PRTA) shares are up following the publishing of an abstract touting its AL amyloidosis treatment

04/23/14 - 03:39 PM EDT

Why Biogen (BIIB) Stock Is Down Today

Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today

04/23/14 - 01:55 PM EDT

Google Develops Glucose-Detectable Contact Lens

Google Develops Glucose-Detectable Contact Lens

  • Tickers in this article:
  • GOOG

It's another potentially huge breakthrough for Google and helpful product for diabetics.

04/23/14 - 10:21 AM EDT

Article
Why Biogen (BIIB) Stock Is Down Today

Why Biogen (BIIB) Stock Is Down Today

Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today

04/23/14 - 01:55 PM EDT

Article
Why Amgen (AMGN) Stock Is Down Today

Why Amgen (AMGN) Stock Is Down Today

  • Tickers in this article:
  • AMGN

Amgen (AMGN) shares are tumbling after missing first quarter revenue guidance.

04/23/14 - 11:01 AM EDT

Article
Why Sanmina (SANM) Stock Is Soaring Today

Why Sanmina (SANM) Stock Is Soaring Today

  • Tickers in this article:
  • SANM

Sanmina (SANM) shares are rising thanks to a second quarter earnings report showing revenue and earnings growth

04/23/14 - 11:33 AM EDT

Video
Gilead's Hepatitis C Drug Solvaldi Delivers Healthy Earnings Gilead's Hepatitis C Drug Solvaldi Delivers Healthy Earnings
  • Tickers in this article:
  • GILD

Gilead delivered healthy earnings thanks to huge sales of its hepatitis C drug Solvaldi, even though insurers are pushing back about the price of the treatment.

04/23/14 - 10:18 AM EDT

Article
Celgene to Rise Like a Phoenix: Opinion

Celgene to Rise Like a Phoenix: Opinion

Celgene's share price offers both growth and value investors something to like.

04/23/14 - 06:21 AM EDT

Article
Why Nektar Therapeutics (NKTR) Stock Is Up Today

Why Nektar Therapeutics (NKTR) Stock Is Up Today

  • Tickers in this article:
  • NKTR
  • JEF

Nektar Therapeutics (NKTR) stock continues to climb following a 'buy' rating by analysts at Jefferies (JEF)

04/22/14 - 03:51 PM EDT

Article
How Obamacare Will Play Out for Big Pharma

How Obamacare Will Play Out for Big Pharma

Obamacare could significantly impact on the ability of pharma giants to sustain their pace of curative and life-saving innovations.

04/23/14 - 06:00 AM EDT

Article
2 Biotech Stocks to Trade (or Not)

2 Biotech Stocks to Trade (or Not)

Here's a look at how to trade some of the most active stocks on the market today.

04/22/14 - 01:37 PM EDT

Article
Pershing Square and Valeant's Allergan Deal a Watershed for Activism

Pershing Square and Valeant's Allergan Deal a Watershed for Activism

  • Tickers in this article:
  • AGN
  • VRX

Pershing Square Capital Management may be re-writing the rules of activist investing after teaming up with Valeant Pharmaceuticals on a potential takeover of Allergan.

04/22/14 - 01:36 PM EDT

Video
Making Sense of Novartis and GlaxoSmithKline's Web of Deals Making Sense of Novartis and GlaxoSmithKline's Web of Deals

The pharmaceutical industry had a deluge of M&A activity on Tuesday as heavyweights Novartis and GlaxoSmithKline announced they were trading $20 billion worth of assets.

04/22/14 - 12:09 PM EDT

Article
Amgen, AT&T and Yum! Brands Lead Today's Earnings: Crunching the Numbers

Amgen, AT&T and Yum! Brands Lead Today's Earnings: Crunching the Numbers

Cree, Discover, Gilead Sciences, Intuitive Surgical, Juniper Networks, Skyworks Solutions and VMWare also report earnings after the closing bell today.

04/22/14 - 08:51 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs